Drawing on electronic health records from nearly 20 million patients with severe obesity, researchers from University of California San Diego find that GLP-1 prescriptions have grown exponentially — from less than 4,600 prescriptions in 2018 to more than 1.4 million in 2025 — according to a new real-world analysis presented today at the annual scientific meeting of the American Society for Metabolic and Bariatric Surgery.